SharePitch
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed
  • Cleantech & Renewables
  • Gaming
  • Twitter Feed

DiaMedica Announces Issuance of European Composition of Matter Patent and Additional Worldwide Filings for DM199

3/20/2017

0 Comments

 
MINNEAPOLIS, Minnesota--(Marketwired) - DiaMedica Therapeutics Inc. (TSX VENTURE:DMA)(DMCAF), today announced that the European Patent Office has issued European Patent No. 2854841, entitled "Human Tissue Kallikrein 1 Glycosylation Isoforms". This patent contains claims that cover the composition of matter of DiaMedica's product candidate, DM199, and pharmaceutical compositions comprising DM199. The patent protects key composition of matter of DM199's proprietary recombinant kallikrien protein. The patent has an expiration date of 2033, which does not include any potential patent term extension.

The expanded patent protection adds European protection to DiaMedica's intellectual property portfolio related to DM199 that includes U.S. Patent No. 9364521 which provides expanded composition of matter protection for DM199.

DiaMedica also recently filed new worldwide patent coverage, including in the U.S., Europe, China and Japan for dosing, route of administration, formulation and for numerous indications that would expire in 2037. The filings was based on recent clinical trial results and related matter.
"We are delighted to announce the issuance of the composition of matter patent in Europe for DM199, which we believe affords broad, foundational composition of matter protection for our compound," commented Rick Pauls, President and CEO of DiaMedica. "We plan to continue to expand and fortify our intellectual property estate for DM199 via expanded worldwide patent coverage including in the U.S., Europe, Japan, and China. We also continue to maintain proprietary manufacturing know-how and trade secrets as we advance DM199 into Phase II clinical trials starting in the upcoming months."

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica's shares are listed on the TSX Venture Exchange under the trading symbol "DMA" and on the OTCQB under the trading symbol "DMCAF". For more information, please vist www.diamedica.com.
0 Comments



Leave a Reply.

    Archives

    November 2020
    October 2020
    July 2020
    June 2020
    March 2020
    February 2020
    November 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017

    Categories

    All
    Avivagen
    DiaMedica
    Fertility
    Heisler Healthcare Weekly
    Medical Device
    Private Equity
    Ventripoint Diagnostics

    RSS Feed

Terms of Use